Auspherix Limited (UK), an early stage anti-infectives company, has appointed Dr Neil Miller as Chief Scientific Officer.
Dr Miller will take full responsibility for driving forward the company’s antibiotic R&D programmes, both in house and through partners, into clinical proof-of-concept studies. The company’s discovery platform has led to the invention of novel compound series with activity against both gram-positive and gram-negative bacteria.
Prior to joining Auspherix, Dr Miller has spent two decades in the pharmaceutical industry at GlaxoSmithKline (GSK), most recently as Senior Director and Head of Chemistry, DMPK & External Discovery in Singapore. In this role he led a research collaboration with the National University of Singapore, to evaluate monoclonal antibodies for the potential treatment of dengue fever. Dr Miller has held a variety of managerial and scientific roles at GSK, including that of Site Head at GSK’s R&D Centre in Singapore.
Dr Miller replaces Professor Ian Charles, co-founder and previously consultant Chief Scientific Officer, who will continue to contribute to the company’s scientific direction as both a member of the Board and as Chair of the Scientific Advisory Board.
